Worth reading
50Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
1380
¥ million (year-on-year increase in net sales for the fiscal year ending June 2027)Wording
Avoiding a definitive answer
How definitive the wording is.Items stated in the management plan
Annual updateNet Sales+22.4%
基準 6,155Target7,535million
Operating profit+39.2%
基準 1,127Target1,569million
Net income for the current fiscal year+7.0%
基準 939Target1,005million
Each line is the climb from the baseline the document states to the target it sets. The slope is scaled against the largest climb in this document. The increase shown by the dotted line is calculated from the two reported figures because the company did not provide the amount of growth.
What happened to the previous plan¥6,150 million → ¥6,155 million（+0.1%）+0.1%Calculated from the two disclosed figures
Statements about the use of capital
Payout ratio / DOE policyThe company plans to pay dividends on an ongoing basis from the fiscal year ending June 2027. The payout ratio will be determined based on a 20% benchmark, while balancing funding for growth investments such as M&A. DOE is Not disclosed.The payout ratio is the proportion of profit paid out as dividends, while DOE is the ratio of dividends to net assets.
Key initiatives
01Further expansion in the number of veterinary hospitals ①
02Further expansion in the number of veterinary hospitals ② National rollout concept
03Growth opportunities through business succession M&A
04Increase in the number of veterinarians
05Increase in revenue per veterinarian
06Launch of sales of "Photo Barrier405"
07Launch of sales of a craft model of the sterilization and deodorization unit
08Toward the social implementation of the efficacy of inactivating avian influenza viruses
09Start of accepting orders for the chitin nanofiber business following the restart of Tottori Factory
10Business expansion in Tottori Prefecture
11Business development involving the advanced use of the veterinary medicine database
12Establishment of a full-fledged CRO and SMO business for veterinary medicine originating in Japan
Plan assumptionsNew M&A and new hospital openings are not incorporated into the earnings forecast because of uncertainty over their timing., Assumes revenue growth from existing businesses and confirmed M&A, Assumes the deployment of approximately 2 veterinarians at each new hospital
Non-financial targetsIndicator Percentage of veterinarians with more than 3 years of experience / Target value More than half / Timing Medium term
Size of the Target MarketThe pet medical market is forecast at ¥550.7 billion (approximately ¥550 billion) in 2026 and ¥622.3 billion in 2027. Sources: Japan Pet Food Association, "2025 National Survey of Dog and Cat Ownership," and Yano Research Institute Ltd., "Pet Business Marketing Overview 2026 Edition."
Risks identified by the company
Regulations under relevant laws and regulations
Number of animals kept as pets
Prices of pharmaceuticals, medical consumables, and medical devices
Securing and developing talent
M&A and business succession
| Item | Details |
|---|---|
| Plan name | Presentation Materials on Business Plans and Growth Potential |
| Plan period | Fiscal year ending June 2027 (next fiscal year's earnings forecast) / No period stated for medium-term targets |
| Progress against the plan | Annual update |
| Sales Target | ¥6,155 million → ¥7,535 million（+22.4%） |
| Operating profit target | ¥1,127 million → ¥1,569 million（+39.3%） |
| Net income target | ¥939 million → ¥1,005 million（+7.0%） |
| Payout ratio / DOE policy | The company plans to pay dividends on an ongoing basis from the fiscal year ending June 2027. The payout ratio will be determined based on a 20% benchmark, while balancing funding for growth investments such as M&A. DOE is Not disclosed. |
| Non-financial targets | Indicator Percentage of veterinarians with more than 3 years of experience / Target value More than half / Timing Medium term |
| Plan assumptions | New M&A and new hospital openings are not incorporated into the earnings forecast because of uncertainty over their timing., Assumes revenue growth from existing businesses and confirmed M&A, Assumes the deployment of approximately 2 veterinarians at each new hospital |
| Key initiatives | Further expansion in the number of veterinary hospitals ①, Further expansion in the number of veterinary hospitals ② National rollout concept, Growth opportunities through business succession M&A, Increase in the number of veterinarians, Increase in revenue per veterinarian, Launch of sales of "Photo Barrier405", Launch of sales of a craft model of the sterilization and deodorization unit, Toward the social implementation of the efficacy of inactivating avian influenza viruses, Start of accepting orders for the chitin nanofiber business following the restart of Tottori Factory, Business expansion in Tottori Prefecture, Business development involving the advanced use of the veterinary medicine database, Establishment of a full-fledged CRO and SMO business for veterinary medicine originating in Japan |
| Results under the previous plan | ¥6,150 million → ¥6,155 million（+0.1%） |
| Size of the Target Market | The pet medical market is forecast at ¥550.7 billion (approximately ¥550 billion) in 2026 and ¥622.3 billion in 2027. Sources: Japan Pet Food Association, "2025 National Survey of Dog and Cat Ownership," and Yano Research Institute Ltd., "Pet Business Marketing Overview 2026 Edition." |
| Risks identified | Regulations under relevant laws and regulations, Number of animals kept as pets, Prices of pharmaceuticals, medical consumables, and medical devices, Securing and developing talent, M&A and business succession |
| Publication date | September 2026 |
Items this document does not state (11)
Operating profit margin targetROE targetROIC targetTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planInvestment amount by sectorSegment targetReason for revision or withdrawalDate of board resolution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.New M&A and new hospital openings are not incorporated into the earnings forecast because of uncertainty over their timing. The forecast assumes revenue growth from existing businesses and confirmed M&A. Operating profit is expected to increase through ongoing cost reductions and expansion of businesses outside the highly profitable veterinary hospital network business.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.